Company Profile For NicOx S.A.

NicOx SA is a France-based biopharmaceutical company engaged in the research, development and future commercialization of investigational drugs for the treatment of cardiometabolic and inflammatory diseases. It specializes in the nitric oxide-donating technology. The Company focuses on the development of nitric oxide-donating drugs in two main areas: inflammation and cardiometabolic. NicOx SA’s main products include Naproxcinod and NCX 6560. Naproxcinod is a nitric oxide-donating compound, which is used in the treatment of signs and symptoms of osteoarthritis. NCX 6560 is a nitric oxide-donating derivative of a commonly used statin drug. The Company operates through two wholly owned subsidiaries: NicOx Research Institute Srl, based in Italy, and NicOx Inc, based in the United States. The Company has research alliances with Merck & Co, Inc., Pfizer Inc and Grupo Ferrer Internacional SA and co-development agreements with Orexo AB and TOPIGEN Pharmaceuticals Inc.

BRIEF: For the nine months ended 30 September 2009, NicOx SA's turnover decreased 62% to EUR1.1M. Net loss for the period decreased 20% to EUR39.9M. Turnover reflects significantly decreased demand for the Company's products and services as well as unfavorable markets conditions. Lower net loss for the period reflects a significant decrease in research and development expenses. NicOx SA is a France-based biopharmaceutical company.